Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 in Melanoma
Innovent announced that the first patient has been dosed in its registrational study evaluating IBI363 as Keytruda® in patients with unresectable loc.
March 3, 2025
by PR Newswire
NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma
The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund.
December 17, 2021
by pharmatimes
FDA Approves Merck’s KEYTRUDA® as Adjuvant Treatment for Patients with Stage IIB or IIC Melanoma
Merck announced that the FDA has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.
December 7, 2021
by AmericanPharmaceuticalReview
Merck’s Keytruda obtains FDA approval as adjuvant therapy for melanoma patients
Merck’s anti-PD-1 therapy, Keytruda, has obtained approval from the US Food and Drug Administration (FDA) as an adjuvant therapy for stage IIB or IIC melanoma patients aged 12 years and above.
December 7, 2021
by Pharmaceutical-Business-Review
BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma
BioNTech SE announced that the FDA granted Fast Track Designation for BNT111, an investigational cancer immunotherapy for the potential treatment of advanced melanoma.
November 22, 2021
by AmericanPharmaceuticalReview
Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that...
September 28, 2021
by prnasia
Spotting the Signs of Deadly Melanoma Skin Cancers
Regular skin checks to look for signs of melanoma could save your life.
August 23, 2021
by drugs
Antibiotics may help to treat melanoma
Some antibiotics appear to be effective against a form of skin cancer known as melanoma. Researchers at KU Leuven, Belgium, examined the effect of these antibiotics on patient-derived tumours in mice.
July 23, 2021
by worldpharmanews
U.S. Cancer Mortality Rates Down From 2014 to 2018
Cancer death rates in the United States continued to decline overall from 2014 to 2018, with declines accelerating for lung cancer and melanoma, according to a report published online July 8 in the Journal of the National Cancer Institute.
July 9, 2021
by drugs
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO Combined with KEYTRUDA for Late-Stage Metastatic Melanoma
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration and Supply Agreement with Merck to to evaluate the combination of OncoSec's DNA-plasmid interleukin-12
July 7, 2021
by firstwordpharma
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre announced a strategic partnership in support of patients with resected Stage 2 BRAF-mutant melanoma.
June 30, 2021
by prnasia
BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients
Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial.
May 25, 2021
by pharmatimes